GNH USA

Europe — EMA

Melkart (Vildagliptin)

GNH USA supplies Melkart (Vildagliptin), a DPP‑4 inhibitor for type 2 diabetes mellitus, helping improve glycemic control. Request a quote for global supply.

Vildagliptin

Request sourcing

1
Pack/s

What is Vildagliptin?

Vildagliptin, the active ingredient in Melkart, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control. GNH USA supplies Melkart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Vildagliptin used for?

Melkart (vildagliptin) is used within the DPP‑4 inhibitor class to manage type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycemic control as part of diet and exercise therapy. - Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and HbA1c when used alone. - Type 2 diabetes mellitus (combination therapy): enhances glucose control when added to metformin or other oral agents.

What are the side effects of Vildagliptin?

Adverse reactions to vildagliptin may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms of cold or sinusitis.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Bullous skin disorders: blistering skin conditions such as Stevens‑Johnson syndrome.

What precautions apply to Vildagliptin?

Before initiating therapy with vildagliptin, consider the following precautions. - Renal function monitoring: adjust use in patients with impaired kidney function. - Hepatic impairment: evaluate liver status and use cautiously. - Elderly patients: start at lower doses and monitor for hypoglycemia. - History of pancreatitis: avoid or use only with close supervision. - Concomitant hypoglycemic agents: assess risk of low blood sugar. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Vildagliptin interact with?

Vildagliptin may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycemia when combined. - Sulfonylureas: heightened hypoglycemia potential. - Strong CYP3A4 inhibitors: may raise vildagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce vildagliptin exposure, diminishing effect. - Digoxin: possible increase in digoxin concentrations. - ACE inhibitors: monitor renal function and potassium levels.

Frequently asked questions

What is Melkart used for?+
Melkart contains vildagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It is prescribed to improve blood‑glucose control when used with diet, exercise, and possibly other antidiabetic agents.
How does vildagliptin work?+
Vildagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood‑sugar levels.
What is the usual dose of Melkart?+
The appropriate dose of Melkart is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Melkart safe during pregnancy or breastfeeding?+
Safety of vildagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.
How do I order Melkart from GNH USA?+
To order Melkart, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Melkart compare with other DPP‑4 inhibitors?+
Melkart (vildagliptin) shares the same mechanism of DPP‑4 inhibition as other agents in its class, such as sitagliptin or saxagliptin. Differences may lie in pharmacokinetic profiles, dosing frequency, and specific safety data, which are evaluated by clinicians when selecting the most appropriate therapy for an individual patient.
What are the storage and handling requirements for Melkart?+
Melkart should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.
How is Melkart administered?+
Melkart is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise instructed.
What are the most serious risks associated with Melkart?+
Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and hepatic dysfunction. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver injury.
Who should not use Melkart?+
Melkart is contraindicated in patients with a known hypersensitivity to vildagliptin or any of its excipients. It should also be avoided in individuals with a history of pancreatitis or severe hepatic impairment unless a specialist determines that benefits outweigh risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Vildagliptin
Route
Oral Use
Manufacturer
G.L. Pharma Gmbh
Origin
EU

Related products

Agartha

Agartha

Vildagliptin

Gedeon Richter Plc.
EU
Agartha

Agartha

Vildagliptin

Gedeon Richter România S.A.
EU
Aglimon

Aglimon

Vildagliptin

Sapiens Pharmaceuticals Ltd
EU
Agnis

Agnis

Vildagliptin

Belupo D.D.
EU